Latest News

All Articles

Filter by:
Topic
Journal Club

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

June 01, 2023

AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with hormone receptor–positive advanced breast cancer are limited.

Advocacy

Oncology Experts Join Together to Provide Best Possible Care for Adolescents and Young Adults with Cancer

May 23, 2023

The Hematology/Oncology Pharmacy Association (HOPA) has partnered with Stupid Cancer, the leader in young adult cancer advocacy, research, and support, to develop tools for healthcare providers who serve the adolescent and young adult (AYA) patient commun

Pharmacist's Application to Practice: Epcoritamab-bysp

May 19, 2023

Shaniya Pleasant, PharmD/MHCI Candidate and Bradley Yelvington, PharmD, BCOP from Vanderbilt University Medical Center write about epcoritamab-bysp

Tools and Resources Late Breaking News

Immune Checkpoint Inhibitors Make Great Strides in Hepatocellular Carcinoma

May 18, 2023

STRIDE presents an alternative first-line choice for patients with unresectable HCC with a manageable side effect profile and a 22% reduction in risk of death over sorafenib

Pharmacists at work
Membership

Reflections from a Life-long Oncology Pharmacist: “Unconditional Care”

May 17, 2023

Siu Fun Wong, PharmD, FASHP, FCSHP Clinical Professor (Volunteer) Division of Hematology/Oncology, Department of Medicine UCI Health, Orange, CA

Mantle-Cell Lymphoma
Journal Club

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma

May 16, 2023

Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi) pretreated mantle-cell lymphoma (M

Oncology pharmacy practice in the United States: Results of a comprehensive, nationwide survey

May 16, 2023

The survey was developed by the HOPA Practice Outcomes and Professional Benchmarking Committee (POPBC) and distributed between March 2021 and January 2022

colonoscopy image
HOPA News Late Breaking News

Late-Breaking HOPA News: Colorectal Cancer Screening Updates & Review of NordICC

March 24, 2023

The Nordic-European Initiative on Colorectal Cancer (NordICC) trial is the first randomized controlled trial (RCT) to evaluate efficacy of CRC screening on risk of CRC development and related death.

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Retifanlimab-dlwr

March 22, 2023

Bernard Marini, PharmD, BCOP, Clinical Pharmacist Specialist at University of Michigan College of Pharmacy writes about Retifanlimab-dlwr.

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Pirtobrutinib

January 27, 2023

Andy Hawn, 2025 PharmD Candidate and Erin Kelley, PharmD, BCOP at the Masonic Cancer Clinic Infusion Pharmacy write about Pirtobrutinib

Drug Updates

Pharmacist’s Application to Practice: Elacestrant

January 27, 2023

Monica Chintapenta, PharmD, BCOP, Pharmacist Clinical Specialist at Parkland Health and Hospital Systems writes about Elacestrant

Tools and Resources Late Breaking News

BPS Announces Professional Development Programs Approved for the Recertification of Board-Certified Pharmacists beginning in January 2024

January 18, 2023

BPS Announces Professional Development Programs Approved for the Recertification of Board-Certified Pharmacists beginning in January 2024